Division of Hematology and Oncology

September 13, 2022

Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial

Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.

By Tom Wilemon
August 29, 2022

Blood cancer progression

Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.

By Leigh MacMillan
August 18, 2022

Abramson, Eng, Johnson named to new VICC roles

Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.

By Tom Wilemon
August 17, 2022

Trial for colorectal cancer drug reaches primary endpoint

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.

By Tom Wilemon
August 11, 2022

Cell-free breast cancer “biopsy”

The circulating DNA that tumors release is a reliable metric of tumor genomics and can be used to monitor molecular changes in metastatic breast cancer.

By Sarah E. Glass
Pregnant woman holding pill pack
August 2, 2022

Targeted cancer drug during pregnancy

The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.

By Leigh MacMillan
July 28, 2022

Study reveals need for matching targeted therapies with EGFR subtypes

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
By Tom Wilemon
June 16, 2022

Breast cancer biomarkers of response

Vanderbilt researchers have identified blood-based biomarkers associated with complete responses to neoadjuvant chemotherapy in patients with breast cancer.
By Joshua Baker
May 26, 2022

Conquer Cancer awards given to five hematology-oncology fellows

Five Vanderbilt University Medical Center hematology and oncology fellows will receive awards from Conquer Cancer, the ASCO Foundation, during the 2022 American Society of Clinical Oncology Annual Meeting in Chicago, June 3-7.
By Tom Wilemon
May 6, 2022

Janet Darnell received a lifesaving lung transplant. Five months later she received lifesaving surgery for colon cancer. She calls herself a “walking miracle.”

Without the lung transplant, the cancer may never have been detected.
By Matt Batcheldor
April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.
By Leigh MacMillan
April 21, 2022

Biltibo receives career development award to support hematology research

Vanderbilt's Eden Biltibo, MD, a clinical fellow in the Division of Hematology and Oncology, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award.
By Tom Wilemon
March 24, 2022

Berlin named interim leader of Hematology and Oncology

Jordan Berlin, MD, has been appointed interim leader of Vanderbilt's Division of Hematology and Oncology in the Department of Medicine.
By Tom Wilemon